ClinicalTrials.gg
RecruitingNCT07779616Updated Nov 6, 2026

Study of PTC844 in Participants With Active Rheumatoid Arthritis

A Phase 2 interventional study of PTC844 and Placebo in Rheumatoid Arthritis, sponsored by PTC Therapeutics. Recruiting at 26 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 6, 2026Now RecruitingFirst sites in 4 new countries+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
466th of 771
75 · median 120
Started
2026
with 20 others
Phase 2
215 of 975
12 open now
Primary completion
2027-09
later than 58 of 120 live
Registered
970th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 466th largest by planned enrollment of the 771 interventional ones that give a count, is one of 21 that started in 2026, is one of 215 in phase 2, reaches primary completion later than 58 of the 120 other live ones, and was the 970th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Immune-mediated disease
  • Autoimmune disease
  • Dihydroorotate dehydrogenase (DHODH) inhibitors
  • PTC844
  • Rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Historical diagnosis of RA as per the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) diagnostic criteria.
  • Active RA disease with a threshold of moderate activity or higher as confirmed via DAS28-CRP (score of ≥3.2) at screening.
  • Naïve to disease-modifying treatments for RA or have had an inadequate response to background treatment for RA and/or inability to tolerate disease-modifying antirheumatic drugs, as per investigator's discretion.
  • Disease-modifying antirheumatic drugs should be stable and unchanged from 30 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study.
  • CRP of ≥5 milligrams (mg)/liter (L) at screening.

Key Exclusion Criteria:

  • Presence of any abnormality at screening, or prior or ongoing medical condition (for example, concomitant illness, psychiatric condition), surgical procedure, medical history, or physical findings that, in the investigator's opinion, could adversely affect the safety of the participant or could impair the assessment of study results.
  • Participants with Class IV RA.
  • Past medical history of blood dyscrasia, bone marrow abnormality and/or suppression, drug induced thrombocytopenia or idiopathic thrombocytopenia, or bleeding diathesis.
  • Past medical history of inflammatory joint disease other than RA or fibromyalgia.
  • Rheumatoid arthritis onset at \<17 years of age.
  • Past medical history of within 5 years prior to screening, except for nonmelanoma skin cancers cursed via local resection.
  • Participant has a known to any of the ingredients of PTC844 or to any of the study drug.
  • Use or intended use of any prescribed disease-modifying treatments for RA within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit, except for methotrexate, low dose prednisone (\<10 mg/day), hydroxychloroquine, or sulfasalazine, which are permitted as established background single-therapy medications.
  • Use or intended use of a combination of methotrexate, low dose prednisone (\<10 mg/day), hydroxychloroquine, or sulfasalazine within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    PTC844 Low Dose

    Participants will receive PTC844 at a low dose once daily (QD) orally for 12 weeks.

    Drug: PTC844

  • Experimental
    PTC844 High Dose

    Participants will receive PTC844 at a high dose QD orally for 12 weeks.

    Drug: PTC844

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to PTC844 QD orally for 12 weeks.

    Drug: Placebo

Interventions

  • DrugPTC844

    PTC844 will be administered per schedule specified in the arm description.

  • DrugPlacebo

    Placebo matching to PTC844 will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Week 16

  2. Change From Baseline to Week 2 in Dihydroorotate (DHO)

    Time frame: Baseline, Week 2

Secondary outcomes

  1. Change From Baseline to Week 12 in C-reactive Protein (CRP)

    Time frame: Baseline, Week 12

  2. Change From Baseline to Week 12 in Erythrocyte Sedimentation Rate (ESR)

    Time frame: Baseline, Week 12

  3. Change From Baseline in DHO Over Time

    Time frame: Baseline up to Week 16

  4. Maximum Observed Plasma Concentration (Cmax) of PTC844

    Time frame: Baseline up to Week 16

  5. Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast)

    Time frame: Baseline up to Week 16

  6. Time to Reach Cmax (Tmax)

    Time frame: Baseline up to Week 16

  7. Number of Participants Achieving ≥20% Improvement in American College of Rheumatology Score (ACR20)

    Time frame: Week 12

  8. Number of Participants Achieving ≥50% Improvement in American College of Rheumatology Score (ACR50)

    Time frame: Week 12

  9. Number of Participants Achieving ≥70% Improvement in American College of Rheumatology Score (ACR70)

    Time frame: Week 12

  10. Change From Baseline to Week 12 in 28-Joint Disease Activity Score-CRP (DAS28-CRP)

    Time frame: Baseline, Week 12

  11. Change From Baseline to Week 12 in 28-Joint Disease Activity Score-ESR (DAS28-ESR)

    Time frame: Baseline, Week 12

  12. Change From Baseline to Week 12 in 20- Item Disability Scale and Heath Assessment Questionnaire (HAQ-DI)

    Time frame: Baseline, Week 12

07

Study locations

6 of 26 sites recruiting
  • AARA Clinical Research - Arizona Arthritis and Rheumatology Associates - Chandler
    Chandler, Arizona 85210, United States
    Recruiting
    • Amer Al-Khoudari · Principal investigator
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff
    Flagstaff, Arizona 86001, United States
    Not yet recruiting
    • Alexander Hu · Principal investigator
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix
    Phoenix, Arizona 85032, United States
    Not yet recruiting
    • Nikila Kumar · Principal investigator
  • Millennium Clinical Trials
    Westlake Village, California 91361, United States
    Recruiting
    • Tony Makhlouf · Principal investigator
  • Nouvelle Clinical Research LLC
    Cutler Bay, Florida 33189, United States
    Recruiting
    • Rawan Jumean · Principal investigator
  • Vitaly Clinical Research, LLC
    Miami, Florida 33125, United States
    Not yet recruiting
    • Pedro San Martin Parra · Principal investigator
  • Millennium Medical Research, LLC.
    Miami, Florida 33126, United States
    Recruiting
    • Ramon Moreda · Principal investigator
  • Suncoast Clinical Research, Inc. - New Port Richey
    New Port Richey, Florida 34652, United States
    Not yet recruiting
    • Farrukh Zaidi · Principal investigator
  • Conquest Research
    Winter Park, Florida 32789, United States
    Recruiting
    • Anand Patel · Principal investigator
  • Chicago Arthritis and Regenerative Medicine
    Chicago, Illinois 60611, United States
    Not yet recruiting
    • Siddharth Tambar · Principal investigator
  • DJL Clinical Research PLLC
    Charlotte, North Carolina 28211, United States
    Not yet recruiting
    • Jane (Emily) Box · Principal investigator
  • Rheumatology Specialty Center
    Willow Grove, Pennsylvania 19090, United States
    Not yet recruiting
    • Elana Eisner · Principal investigator
  • Precision Comprehensive Clinical Research Solutions - Irving
    Irving, Texas 76051, United States
    Recruiting
    • Renuka Basavaraju · Principal investigator
  • Arthritis & Rheumatism Associates - Fairfax
    Fairfax, Virginia 22031, United States
    Not yet recruiting
    • Daniel El-Bogdadi · Principal investigator
  • Aversi Clinic LLC
    Tbilisi, Georgia
    Not yet recruiting
    • Irine Malazonia · Principal investigator
  • JSC Jerarsi
    Tbilisi, Georgia
    Not yet recruiting
    • Rima Akhvlediani · Principal investigator
  • JSC Vian - Iv. Bokeria University Hospital
    Tbilisi, Georgia
    Not yet recruiting
    • Rusudan Bibilashvili · Principal investigator
  • JSC VIAN Caraps Medline
    Tbilisi, Georgia
    Not yet recruiting
    • Manana Zodelava · Principal investigator
  • LTD Caucasus Medical Centre
    Tbilisi, Georgia
    Not yet recruiting
    • Marina Toidze · Principal investigator
  • LTD Innova
    Tbilisi, Georgia
    Not yet recruiting
    • Luba Lagvilava · Principal investigator
  • The First Medical Center LLC
    Tbilisi, Georgia
    Not yet recruiting
    • Tamta Kobakhidze · Principal investigator
  • CAP Research ltd
    Quatre Bornes, Mauritius
    Not yet recruiting
    • Poojdev Jhugroo · Principal investigator
  • Arthritis Clinical Research Trials CC
    Cape Town, South Africa
    Not yet recruiting
    • Catherine Spargo · Principal investigator
  • Dr IC Louw
    Cape Town, South Africa
    Not yet recruiting
    • CI Louw · Principal investigator
  • Clinresco Centres (Pty) Ltd
    Kempton Park, South Africa
    Not yet recruiting
    • Jennifer Rosa · Principal investigator
  • Clinical Trials Network - Helderberg
    Somerset West, South Africa
    Not yet recruiting
    • Gareth Tarr · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 12 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 21, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Oct 29, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
26 sites added — first sites in Georgia, Mauritius, South Africa and United States
Show 26 added (14 United States, 7 Georgia, 4 South Africa, 1 Mauritius)
  • AARA Clinical Research - Arizona Arthritis and Rheumatology Associates - Chandler · Chandler, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff · Flagstaff, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix · Phoenix, United States
  • Millennium Clinical Trials · Westlake Village, United States
  • Nouvelle Clinical Research LLC · Cutler Bay, United States
  • Vitaly Clinical Research, LLC · Miami, United States
  • Millennium Medical Research, LLC. · Miami, United States
  • Suncoast Clinical Research, Inc. - New Port Richey · New Port Richey, United States
  • Conquest Research · Winter Park, United States
  • Chicago Arthritis and Regenerative Medicine · Chicago, United States
  • DJL Clinical Research PLLC · Charlotte, United States
  • Rheumatology Specialty Center · Willow Grove, United States
  • Precision Comprehensive Clinical Research Solutions - Irving · Irving, United States
  • Arthritis & Rheumatism Associates - Fairfax · Fairfax, United States
  • Aversi Clinic LLC · Tbilisi, Georgia
  • JSC Jerarsi · Tbilisi, Georgia
  • JSC Vian - Iv. Bokeria University Hospital · Tbilisi, Georgia
  • JSC VIAN Caraps Medline · Tbilisi, Georgia
  • LTD Caucasus Medical Centre · Tbilisi, Georgia
  • LTD Innova · Tbilisi, Georgia
  • The First Medical Center LLC · Tbilisi, Georgia
  • CAP Research ltd · Quatre Bornes, Mauritius
  • Arthritis Clinical Research Trials CC · Cape Town, South Africa
  • Dr IC Louw · Cape Town, South Africa
  • Clinresco Centres (Pty) Ltd · Kempton Park, South Africa
  • Clinical Trials Network - Helderberg · Somerset West, South Africa
Nov 6, 2026
Start date
Aug 31, 2026→Sep 24, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    26 sites added — first sites in Georgia, Mauritius, South Africa and United States
    Show 26 added (14 United States, 7 Georgia, 4 South Africa, 1 Mauritius)
    • AARA Clinical Research - Arizona Arthritis and Rheumatology Associates - Chandler · Chandler, United States
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff · Flagstaff, United States
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix · Phoenix, United States
    • Millennium Clinical Trials · Westlake Village, United States
    • Nouvelle Clinical Research LLC · Cutler Bay, United States
    • Vitaly Clinical Research, LLC · Miami, United States
    • Millennium Medical Research, LLC. · Miami, United States
    • Suncoast Clinical Research, Inc. - New Port Richey · New Port Richey, United States
    • Conquest Research · Winter Park, United States
    • Chicago Arthritis and Regenerative Medicine · Chicago, United States
    • DJL Clinical Research PLLC · Charlotte, United States
    • Rheumatology Specialty Center · Willow Grove, United States
    • Precision Comprehensive Clinical Research Solutions - Irving · Irving, United States
    • Arthritis & Rheumatism Associates - Fairfax · Fairfax, United States
    • Aversi Clinic LLC · Tbilisi, Georgia
    • JSC Jerarsi · Tbilisi, Georgia
    • JSC Vian - Iv. Bokeria University Hospital · Tbilisi, Georgia
    • JSC VIAN Caraps Medline · Tbilisi, Georgia
    • LTD Caucasus Medical Centre · Tbilisi, Georgia
    • LTD Innova · Tbilisi, Georgia
    • The First Medical Center LLC · Tbilisi, Georgia
    • CAP Research ltd · Quatre Bornes, Mauritius
    • Arthritis Clinical Research Trials CC · Cape Town, South Africa
    • Dr IC Louw · Cape Town, South Africa
    • Clinresco Centres (Pty) Ltd · Kempton Park, South Africa
    • Clinical Trials Network - Helderberg · Somerset West, South Africa
    Start date Aug 31, 2026→Sep 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07779616
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Sep 24, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 29, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Patient Advocacy
Contact
medinfo@ptcbio.com
1-866-562-4620

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion